Cargando…
Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential
Nipah virus (NiV) disease is a bat-borne zoonosis responsible for outbreaks with high lethality and is a priority for vaccine development. With funding from the Coalition of Epidemic Preparedness Innovations (CEPI), we are developing a chimeric vaccine (PHV02) composed of recombinant vesicular stoma...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9269911/ https://www.ncbi.nlm.nih.gov/pubmed/35759511 http://dx.doi.org/10.1371/journal.ppat.1010658 |
_version_ | 1784744336874799104 |
---|---|
author | Monath, Thomas P. Nichols, Richard Tussey, Lynda Scappaticci, Kelly Pullano, Thaddeus G. Whiteman, Mary D. Vasilakis, Nikos Rossi, Shannan L. Campos, Rafael Kroon Azar, Sasha R. Spratt, Heidi M. Seaton, Brent L. Archambault, W. Tad Costecalde, Yanina V. Moore, Evan H. Hawks, Roger J. Fusco, Joan |
author_facet | Monath, Thomas P. Nichols, Richard Tussey, Lynda Scappaticci, Kelly Pullano, Thaddeus G. Whiteman, Mary D. Vasilakis, Nikos Rossi, Shannan L. Campos, Rafael Kroon Azar, Sasha R. Spratt, Heidi M. Seaton, Brent L. Archambault, W. Tad Costecalde, Yanina V. Moore, Evan H. Hawks, Roger J. Fusco, Joan |
author_sort | Monath, Thomas P. |
collection | PubMed |
description | Nipah virus (NiV) disease is a bat-borne zoonosis responsible for outbreaks with high lethality and is a priority for vaccine development. With funding from the Coalition of Epidemic Preparedness Innovations (CEPI), we are developing a chimeric vaccine (PHV02) composed of recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoproteins of both Ebola virus (EBOV) and NiV. The EBOV glycoprotein (GP) mediates fusion and viral entry and the NiV attachment glycoprotein (G) is a ligand for cell receptors, and stimulates neutralizing antibody, the putative mediator of protection against NiV. PHV02 is identical in construction to the registered Ebola vaccine (Ervebo) with the addition of the NiV G gene. NiV ephrin B2 and B3 receptors are expressed on neural cells and the wild-type NiV is neurotropic and causes encephalitis in affected patients. It was therefore important to assess whether the NiV G alters tropism of the rVSV vector and serves as a virulence factor. PHV02 was fully attenuated in adult hamsters inoculated by the intramuscular (IM) route, whereas parental wild-type VSV was 100% lethal. Two rodent models (mice, hamsters) were infected by the intracerebral (IC) route with graded doses of PHV02. Comparator active controls in various experiments included rVSV-EBOV (representative of Ebola vaccine) and yellow fever (YF) 17DD commercial vaccine. These studies showed PHV02 to be more neurovirulent than both rVSV-EBOV and YF 17DD in infant animals. PHV02 was lethal for adult hamsters inoculated IC but not for adult mice. In contrast YF 17DD retained virulence for adult mice inoculated IC but was not virulent for adult hamsters. Because of the inconsistency of neurovirulence patterns in the rodent models, a monkey neurovirulence test (MNVT) was performed, using YF 17DD as the active comparator because it has a well-established profile of quantifiable microscopic changes in brain centers and a known reporting rate of neurotropic adverse events in humans. In the MNVT PHV02 was significantly less neurovirulent than the YF 17DD vaccine reference control, indicating that the vaccine will have an acceptable safety profile for humans. The findings are important because they illustrate the complexities of phenotypic assessment of novel viral vectors with tissue tropisms determined by transgenic proteins, and because it is unprecedented to use a heterologous comparator virus (YF vaccine) in a regulatory-enabling study. This approach may have value in future studies of other novel viral vectors. |
format | Online Article Text |
id | pubmed-9269911 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-92699112022-07-09 Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential Monath, Thomas P. Nichols, Richard Tussey, Lynda Scappaticci, Kelly Pullano, Thaddeus G. Whiteman, Mary D. Vasilakis, Nikos Rossi, Shannan L. Campos, Rafael Kroon Azar, Sasha R. Spratt, Heidi M. Seaton, Brent L. Archambault, W. Tad Costecalde, Yanina V. Moore, Evan H. Hawks, Roger J. Fusco, Joan PLoS Pathog Research Article Nipah virus (NiV) disease is a bat-borne zoonosis responsible for outbreaks with high lethality and is a priority for vaccine development. With funding from the Coalition of Epidemic Preparedness Innovations (CEPI), we are developing a chimeric vaccine (PHV02) composed of recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoproteins of both Ebola virus (EBOV) and NiV. The EBOV glycoprotein (GP) mediates fusion and viral entry and the NiV attachment glycoprotein (G) is a ligand for cell receptors, and stimulates neutralizing antibody, the putative mediator of protection against NiV. PHV02 is identical in construction to the registered Ebola vaccine (Ervebo) with the addition of the NiV G gene. NiV ephrin B2 and B3 receptors are expressed on neural cells and the wild-type NiV is neurotropic and causes encephalitis in affected patients. It was therefore important to assess whether the NiV G alters tropism of the rVSV vector and serves as a virulence factor. PHV02 was fully attenuated in adult hamsters inoculated by the intramuscular (IM) route, whereas parental wild-type VSV was 100% lethal. Two rodent models (mice, hamsters) were infected by the intracerebral (IC) route with graded doses of PHV02. Comparator active controls in various experiments included rVSV-EBOV (representative of Ebola vaccine) and yellow fever (YF) 17DD commercial vaccine. These studies showed PHV02 to be more neurovirulent than both rVSV-EBOV and YF 17DD in infant animals. PHV02 was lethal for adult hamsters inoculated IC but not for adult mice. In contrast YF 17DD retained virulence for adult mice inoculated IC but was not virulent for adult hamsters. Because of the inconsistency of neurovirulence patterns in the rodent models, a monkey neurovirulence test (MNVT) was performed, using YF 17DD as the active comparator because it has a well-established profile of quantifiable microscopic changes in brain centers and a known reporting rate of neurotropic adverse events in humans. In the MNVT PHV02 was significantly less neurovirulent than the YF 17DD vaccine reference control, indicating that the vaccine will have an acceptable safety profile for humans. The findings are important because they illustrate the complexities of phenotypic assessment of novel viral vectors with tissue tropisms determined by transgenic proteins, and because it is unprecedented to use a heterologous comparator virus (YF vaccine) in a regulatory-enabling study. This approach may have value in future studies of other novel viral vectors. Public Library of Science 2022-06-27 /pmc/articles/PMC9269911/ /pubmed/35759511 http://dx.doi.org/10.1371/journal.ppat.1010658 Text en © 2022 Monath et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Monath, Thomas P. Nichols, Richard Tussey, Lynda Scappaticci, Kelly Pullano, Thaddeus G. Whiteman, Mary D. Vasilakis, Nikos Rossi, Shannan L. Campos, Rafael Kroon Azar, Sasha R. Spratt, Heidi M. Seaton, Brent L. Archambault, W. Tad Costecalde, Yanina V. Moore, Evan H. Hawks, Roger J. Fusco, Joan Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential |
title | Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential |
title_full | Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential |
title_fullStr | Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential |
title_full_unstemmed | Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential |
title_short | Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential |
title_sort | recombinant vesicular stomatitis vaccine against nipah virus has a favorable safety profile: model for assessment of live vaccines with neurotropic potential |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9269911/ https://www.ncbi.nlm.nih.gov/pubmed/35759511 http://dx.doi.org/10.1371/journal.ppat.1010658 |
work_keys_str_mv | AT monaththomasp recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential AT nicholsrichard recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential AT tusseylynda recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential AT scappaticcikelly recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential AT pullanothaddeusg recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential AT whitemanmaryd recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential AT vasilakisnikos recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential AT rossishannanl recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential AT camposrafaelkroon recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential AT azarsashar recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential AT sprattheidim recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential AT seatonbrentl recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential AT archambaultwtad recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential AT costecaldeyaninav recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential AT mooreevanh recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential AT hawksrogerj recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential AT fuscojoan recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential |